#393 ‒ AMA #85: A guide to medications and supplements: determining what to take, what to skip, and how to know if they're working for you

Summary

Episode Summary: The Peter Attia Drive #393

AMA #85: A Guide to Medications and Supplements – Determining What to Take, What to Skip, and How to Know If They're Working for You
Date: May 25, 2026
Host: Peter Attia, MD

---

Overview & Main Theme

In this Ask Me Anything (AMA) episode, Dr. Peter Attia addresses one of the most frequent—and, in his view, misunderstood—questions in health and longevity: how to rationally approach taking medications and supplements. Rather than asking, "Is this good or bad for me?", Peter insists the better question is, "Does this make sense for me, with my specific problem?" He systematically breaks down how to define health problems, evaluate potential interventions, analyze risk versus benefits, and avoid placebo-driven self-deception—especially in the case of over-the-counter supplements.

---

Key Discussion Points & Insights

1. Defining the Problem Before Picking the Intervention

[00:34 – 05:23]

• Common Mistake: People often start with the intervention—whether a supplement or drug—rather than first clearly defining the health problem they want to address.
• Vague Problem Definitions: Broad goals like "I want to be healthier" or "I want more energy" are not actionable, measurable, or falsifiable.
• Peter’s Framework:
  • Metric: Choose a quantifiable marker (example: "My APOB is 130 mg/dL. I want to get it below 60 mg/dL").
  • Threshold: Identify the level at which there's a problem.
  • Timeline: Set a realistic timeframe for the expected improvement.
• Consequences of Vague Goals: Without clear metrics and timelines, people may continue interventions for years without knowing if they've made a real difference.
• Quote:
  • “Do not start with the molecule. Start with the problem. Define tightly enough that you could actually be proven wrong.” – Peter Attia [05:12]
• Example:
  • Rather than "my sleep is bad," specify: "It takes me 60 minutes to fall asleep on 4–5 nights a week. I want to get that under 10 minutes within two months."

---

2. Classifying the "Job" of the Supplement or Medication

[05:23 – 09:27]

• The Four "Jobs":
  1. Disease Treatment:
     • Highest evidence bar & risk acceptance; targeting a clear disease state.
  2. Symptom Relief:
     • Focus on lived, subjective improvement; may tolerate placebo effects if downside risk is low.
  3. Risk Reduction:
     • Treating unseen risks (e.g., high cholesterol); needs strong evidence, validated markers.
  4. Optimization:
     • Error rates are highest; interventions often proposed for small, difficult-to-measure improvements in healthy people.
• Why This Matters:
  • Many "longevity" or "optimization" claims borrow language from risk reduction but lack the evidence required for real prevention claims.
• Guiding Principle:
  • The more concrete and severe the problem, the more risk you might accept and the stronger the evidence must be.
  • For speculative or optimization goals, increase skepticism, demand higher safety, and lower tolerance for risk.
• Quote:
  • “If the job is optimization, then I think skepticism should go up. This is where error rates are highest.” – Peter Attia [08:39]

---

3. Evaluating Evidence Quality and Avoiding Self-Deception

[09:27 – 09:59] – Teaser for Full Episode

• Common Pitfalls:
  • People conflate levels of evidence—confusing mechanistic or animal studies with robust clinical trials.
• Previewed Solution:
  • Dr. Attia teases a detailed discussion (in the full episode) on how to spot strong versus weak evidence, why mechanism isn’t enough, and how to protect oneself from misleading claims.

---

Memorable Quotes

• “Poor problem definition almost guarantees some sort of false positive... That’s how people end up taking things for years without knowing if they’ve solved anything real.” – Peter Attia [04:53]
• “The challenge... is in part because most of the longevity interventions are really optimizations masquerading as risk reductions.” – Peter Attia [08:03]
• “Not all biomarkers are equal... APOB is a very well validated surrogate biomarker, whereas some vague inflammatory marker or heavy metal is not necessarily going to be in that category.” – Peter Attia [07:30]

---

Timestamps for Key Segments

• [00:34] Introduction — Framing the episode's objectives
• [02:07] How to define a health problem before considering an intervention
• [03:58] Example of translating vague health goals into concrete metrics
• [05:23] The four "job" categories for drugs and supplements
• [08:03] Why "longevity" products often blur the lines between risk reduction and optimization
• [09:27] Moving into discussion of evaluating evidence quality (continued in premium/full episode)

---

Tone and Language

Dr. Attia maintains a highly analytical, practical, and occasionally skeptical tone. He mixes clinical insights with relatable analogies and cautions listeners against self-delusion, hype, and vague health goals.

---

Summary

This episode serves as a masterclass in critical thinking for anyone considering medications or supplements. Peter Attia urges listeners:

• Start with a clear, measurable definition of your problem.
• Classify what you want an intervention to do (treat, relieve, reduce risk, optimize).
• Raise your standards for evidence accordingly—especially for vague or "optimization" goals.
• Stay skeptical, especially when the promised benefits are hard to quantify or are based purely on mechanisms rather than robust outcomes.

The episode is essential listening for anyone aiming to make rational, evidence-informed choices about adding—or skipping—medications and supplements in pursuit of health and longevity.

Transcript

[Peter Attia]

Foreign.

[Podcast Host/Announcer]

Hey everyone, welcome to a Sneak Peek, Ask Me Anything or AMA episode of the Drive podcast. I'm your host, Peter Attia.

[Peter Attia]

At the end of this short episode,

[Podcast Host/Announcer]

I'll explain how you can access the AMA episodes in full, along with a

[Peter Attia]

ton of other membership benefits we've created. Or you can learn more now by

[Podcast Host/Announcer]

going to peterattiamd.com subscribe so without further delay, here's today's sneak peek of the

[Peter Attia]

Ask Me Anything episode. Welcome to ask me anything AMA episode 85. Today we're talking about medications and supplements. This is one of the topics I get asked about more than almost anything else. And I think it's also one of the easiest areas to go wrong. People tend to ask me whether something is good or bad, whether they should take it or not. But those are, I think, kind of the wrong questions. The right question is whether a specific intervention makes sense for a specific person with a specific problem. And that's what I'm going to try to get to today. So in this episode we'll cover why defining the problem matters more than picking the intervention. The different jobs a medication or supplement can do, and why the evidence bar should move depending on the job. How to tell strong evidence from weak evidence and why mechanism alone isn't enough. Why baseline risk changes everything and how relative risk can mislead you. How to think about the real downside of taking something. Side effects, yes, but also cost, hassle and opportunity cost. How to determine whether the supplement you're taking is having any real effect. How to stop taking something. Why supplements specifically deserve a lot more skepticism than people give them. And finally, the short list of over the counter supplements that I think are probably worth the risk, reward, trade off. So without further delay, I hope you

[Podcast Host/Announcer]

enjoy AMA number 85.

[AMA Questioner]

Peter, welcome to another ama. How you doing?

[Peter Attia]

Very well, thanks.

[AMA Questioner]

Good. We will get right into it today on AMA all around medications and supplements. So first question, before someone takes any medication or supplement, how do you think that they should define what the problem is in a way that increases the odds that they look for and pick interventions that actually benefit them and reduce risk, opposed to at best waste money and at worse cause other harm that they don't know about?

[Peter Attia]

You know, I think this is actually one of the biggest challenges from a, from a sort of mental model standpoint is plaguing most people when they think about supplements in particular, but I think also frankly pharmaceuticals. So people are, I think, typically defining the problem at the wrong level of abstraction. So they'll say things like I want to be healthier or I want more energy, or I want to pursue better longevity. And the challenge is that those are not really actionable problem definitions. They're vague, difficult to measure, very difficult to falsify, and things like that. So I would suggest that we reframe this discussion around what would be actionable metrics or actionable parts. Right? So one would be a metric that can be studied. Two would be a threshold against which you would measure. And then I think a third potential one would be a time horizon. So what am I measuring? What level tells me that there's a problem and by extension, a solution? And when do I expect that to happen? And so if you can't come up a priori with some sense of those things, you're probably not in a good spot to start anything. So, for example, let's use. Use a tangible example. Instead of saying, my cholesterol is bad, you would say, my APOB is 130 milligrams per deciliter. I want to get it below 60 milligrams per deciliter.

[Podcast Host/Announcer]

And I'd like to do that in

[Peter Attia]

the next six months. Instead of saying, you know, my sleep is bad, you might say, it takes me 60 minutes to fall asleep on, you know, four or five nights a week. And I want to make that under 10 minutes to fall asleep within two months. So that's a real problem definition. The next question is the counterfactual, what happens if I do nothing? Does this problem meaningfully increase risk, reduce quality of life, or create some downstream consequence? So I think this question is important because it separates real problems from things that merely, you know, feel actionable. And it matters because poor, poor problem definition almost guarantees some sort of false positive. So if the problem is vague, almost anything can look like it helped you sleep a little better one week, your energy is a little better. On Tuesday, one lab improves a little, and now you're telling yourself a story. And we all do this. I mean, that's. We're storytelling machines. And I think that's how people end up taking things for years without ever knowing if they've solved anything real. So I think the rule here could be pretty simple, right? Do not start with the molecule. Start with the problem. Define tightly enough that you could actually be proven wrong. So if you can't state the metric, the threshold, and the timeline and even the consequences of doing nothing, you're not really making an intervention decision. You're probably impulse shopping on, you know, your favorite website.

[AMA Questioner]

And when looking at different medications and supplements, how do you think about and maybe classify the quote unquote job that they would do. And based on that classification, does it change the evidence threshold you like to see and how much risk you're willing to tolerate?

[Peter Attia]

Well, once the problem is defined, I think the next question is asking, okay, what is the purpose of that intervention? And again, it matters because it requires different standards. So if you don't classify this job as you describe it correctly, you're, you're very likely going to apply the wrong evidence threshold and accept the wrong amount of risk. So I think we could put these into four buckets. Disease treatment, symptom relief, risk reduction. And I hate the term, but I think we just need to use it and it's optimization. So they might sound sort of similar on the surface, but they're actually quite, quite different. So if the, if the quote unquote job is disease treatment, the bar is high, right? Does this improve the disease in a meaningful way? And of course here you would be willing to accept more downside because the underlying problem is serious and the counterfactual is strong. Presumably if you have a disease and you do nothing, the disease will get significantly worse. But at the same time you're going to want stronger evidence, ideally hard outcome trials or at least some well validated surrogate endpoint, not just a compelling story. Now, if the job is symptom relief, the question is a bit different. Does the person actually feel or function better? And here we're dealing with something that's subjective. You may be willing to frankly tolerate placebo risk because if the symptoms meaningfully improve and the downside is low, that could still be a reasonable trade off. If the job is risk reduction, you're treating something that a person can't feel almost by definition. So the evidence bar again here needs to be pretty high. That usually means hard outcomes when available, or again, at least a very validated surrogate marker. And again, not all biomarkers are equal here. APOB is a very well validated surrogate biomarker. Whereas, you know, some vague inflammatory marker or, or heavy metal is not necessarily going to be in that category as you're, you know, someone's pontificating about detoxifications or something like that. If the job is optimization, then I think skepticism should, should go up, right? This is where error rates are highest. The person is usually starting from a relatively healthy baseline and the expected effect is often small. The claims are usually made in a mechanistic way, and there's generally no objective way to determine whether the supplement or medication is is benefiting you, making your ability to basically fool yourself enormous. So I think the challenge, and probably the reason we're even doing this episode, is in part because most of the longevity interventions are really optimizations masquerading as risk reductions. They kind of borrow the language of prevention, aging, health span, resilience, longevity. But the actual evidence that they put forth looks much more like speculative optimization interventions rather than true risk reduction. And I think this distinction really matters, right? This classification should change both your evidence threshold and your risk tolerance. I think the more serious and concrete the problem, the more downside you may be willing to keep, as I said, and the more speculative the goal, the less downside you should be willing to tolerate. So I guess to to summarize that if you're looking at disease treatment, you want to demand strong evidence, but you'll accept more risk if you if you're looking at symptom relief, you prioritize the actual lived benefit. But watch for placebo and noise and factor in the unknowns about safety, risk reduction, you're going to have to look at validated surrogates or hard outcomes, although the latter tends to be challenging. And if it's about optimization, you're going to default into a skeptical state, especially around safety.

[AMA Questioner]

So Peter, let's double click on one of the things you briefly mentioned there, which is kind of evidence when looking at medications and supplements. So when people are evaluating how they're thinking about a medication and supplement for themselves, what are common ways that you see people confuse the different tiers of evidence and how can people prevent that in practice? So how can people be a little bit more aware so when they're looking at various claims, they start to understand how good those claims are.

[Podcast Host/Announcer]

Thank you for listening to today's sneak peek AMA episode of the Drive. If you're interested in in hearing the complete version of this ama, you'll want to become a premium member. It's extremely important to me to provide all of this content without relying on paid ads to do this. Our work is made entirely possible by our members and in return we offer exclusive member only content and benefits above and beyond what is available for free. So if you want to take your knowledge of this space to the next level, it's our goal to ensure members get back much more than the price of the subscription. Premium membership includes several benefits. First, comprehensive podcast show notes that detail every topic, paper, person and thing that we discuss in each episode. And the word on the street is nobody's show notes rival ours. Second, monthly Ask Me Anything or AMA episodes. These episodes are comprised of detailed responses to subscriber questions typically focused on a single topic, and are designed to offer a great deal of clarity and detail on topics of special interest to our members. You'll also get access to the show Notes for these episodes, of course. Third, delivery of our premium newsletter, which is put together by our dedicated team of research analysts. This newsletter covers a wide range of topics related to longevity and provides much more detail than our free weekly newsletter. Fourth, access to our private podcast feed that provides you with access to every episode, including AMAs support sans the spiel you're listening to now and in your regular podcast feed. Fifth, the Qualys, an additional member only podcast we put together that serves as a highlight reel featuring the best excerpts from previous episodes of the Drive. This is a great way to catch up on previous episodes without having to go back and listen to each one of them and finally, other benefits that are added along the way. If you want to learn more and access these member only benefits, you can head over to PeterattiMD.com subscribe. You can also find me on YouTube, Instagram and Twitter, all with the handle Peteratti MD. You can also leave us a review on Apple Podcasts or whatever podcast player you use. This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional healthcare services, including the giving of medical advice. No doctor patient relationship is formed. The use of this information and the materials linked to this podcast is at the user's own risk. The the content on this podcast is not intended to be a substitute for professional medical advice, diagnosis or treatment. Users should not disregard or delay in obtaining medical advice from any medical condition they have, and they should seek the assistance of their healthcare professionals for any such conditions. Finally, I take all conflicts of interest very seriously. For all of my disclosures and the companies I invest in or advise, please visit Peteratti md.com for forward/ about where I keep an up to date and active list of all disclosures.